Contemporary use of real-world data for clinical trial conduct in the United States: a sco** review
Objective Real-world data (RWD), defined as routinely collected healthcare data, can be a
potential catalyst for addressing challenges faced in clinical trials. We performed a sco** …
potential catalyst for addressing challenges faced in clinical trials. We performed a sco** …
The problem of fairness in synthetic healthcare data
Access to healthcare data such as electronic health records (EHR) is often restricted by laws
established to protect patient privacy. These restrictions hinder the reproducibility of existing …
established to protect patient privacy. These restrictions hinder the reproducibility of existing …
Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis
Background Clinicians are less likely to prescribe guideline-recommended treatments to
people with multimorbidity than to people with a single condition. Doubts as to the …
people with multimorbidity than to people with a single condition. Doubts as to the …
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: a nationwide …
Aims To investigate cardiovascular (CV) safety and event rates for dapagliflozin versus other
glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the …
glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the …
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European …
Aims Enrollment criteria vary substantially among cardiovascular outcome trials (CVOTs) of
sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is), which impacts the relationship …
sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is), which impacts the relationship …
Medical concept normalization in clinical trials with drug and disease representation learning
Motivation Clinical trials are the essential stage of every drug development program for the
treatment to become available to patients. Despite the importance of well-structured clinical …
treatment to become available to patients. Despite the importance of well-structured clinical …
Patterns of telemedicine use and glycemic outcomes of endocrinology care for patients with type 2 diabetes
MF Zupa, VG Vimalananda… - JAMA Network …, 2023 - jamanetwork.com
Importance Telemedicine can increase access to endocrinology care for people with type 2
diabetes (T2D), but patterns of use and outcomes of telemedicine specialty care for adults …
diabetes (T2D), but patterns of use and outcomes of telemedicine specialty care for adults …
How many patients with type 2 diabetes meet the inclusion criteria of the cardiovascular outcome trials with SGLT2 inhibitors? Estimations from a population database …
Objective. Regulatory agencies require the assessment of cardiovascular (CV) safety for
new type 2 diabetes (T2D) therapies through CV outcome trials (CVOTs). However, patients …
new type 2 diabetes (T2D) therapies through CV outcome trials (CVOTs). However, patients …
The association between sodium glucose cotransporter‐2 inhibitors vs dipeptidyl peptidase‐4 inhibitors and renal outcomes in people discharged from hospital with …
Background We investigated the association between post‐hospital discharge use of
sodium glucose cotransporter‐2 inhibitors (SGLT‐2is) compared to dipeptidyl peptidase‐4 …
sodium glucose cotransporter‐2 inhibitors (SGLT‐2is) compared to dipeptidyl peptidase‐4 …
Eligibility of Asian and European registry patients for phase III trials in heart failure with reduced ejection fraction
Aims Traditional approaches to designing clinical trials for heart failure (HF) have historically
relied on expertise and past practices. However, the evolving landscape of healthcare …
relied on expertise and past practices. However, the evolving landscape of healthcare …